Clinical Patterns of Traditional Chinese Medicine for Ischemic Heart Disease Treatment: A Population-Based Cohort Study

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2022 Jul 27

PMID 35888597

Authors

Lung-Shuo Wang

Pei-Tzu Yen

Shih-Feng Weng

Jong-Hau Hsu

Jwu-Lai Yeh

Affiliations

Soon will be listed here.

Abstract

Traditional Chinese medicines (TCMs) are widely prescribed to relieve ischemic heart disease (IHD); however, no cohort studies have been conducted on the use of TCMs for patients with IHD. The aim of the study was to analyze TCM prescription patterns for patients with IHD. The retrospective population-based study employed a randomly sampled cohort of 4317 subjects who visited TCM clinics. Data were obtained from the National Health Insurance Research Database (NHIRD) of Taiwan for the period covering 2000 to 2017. Data analysis focused on the top ten most commonly prescribed formulae and single TCMs. We also examined the most common two- and three-drug combinations of TCM in single prescriptions. Demographic characteristics included age and sex distributions. Analysis was performed on 22,441 prescriptions. The majority of TCM patients were male (53.6%) and over 50 years of age (65.1%). Zhi-Gan-Cao-Tang (24.76%) was the most frequently prescribed formulae, and Danshen (28.89%) was the most frequently prescribed single TCM for the treatment of IHD. The most common two- and three-drug TCM combinations were Xue-Fu-Zhu-Yu-Tang and Danshen" (7.51%) and "Zhi-Gan-Cao-Tang, Yang-Xin-Tang, and Gua-Lou-Xie-Bai-Ban-Xia-Tang" (2.79%). Our results suggest that most of the frequently prescribed TCMs for IHD were Qi toning agents that deal with cardiovascular disease through the promotion of blood circulation. The widespread use of these drugs warrants large-scale, randomized clinical trials to investigate their effectiveness and safety.

Citing Articles

Early Detection and One-Year Follow-Up of Subclavian Steal Syndrome Treated With Traditional Chinese Medicine: A Case Report.

Yang W Clin Case Rep. 2025; 13(2):e70147.

PMID: 39868403 PMC: 11761398. DOI: 10.1002/ccr3.70147.

Effect of Harvest Time on Growth and Bioactive Compounds in .

Xing Z, Bi G, Li T, Zhang Q, Knight P Plants (Basel). 2024; 13(13).

PMID: 38999628 PMC: 11243644. DOI: 10.3390/plants13131788.

Inflammation in Coronary Atherosclerosis: Insights into Pathogenesis and Therapeutic Potential of Anti-Inflammatory Drugs.

Figueiredo C, Roseira E, Viana T, Duarte Silveira M, Melo R, Fernandez M Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765050 PMC: 10534546. DOI: 10.3390/ph16091242.

Network pharmacology-based analysis of potential mechanisms of myocardial ischemia-reperfusion injury by total salvianolic acid injection.

Li N, Gu X, Liu F, Zhang Y, Sun Y, Gao S Front Pharmacol. 2023; 14:1202718.

PMID: 37680709 PMC: 10482107. DOI: 10.3389/fphar.2023.1202718.

References

Gong A, Duan R, Wang H, Kong X, Dong T, Tsim K . Evaluation of the Pharmaceutical Properties and Value of Astragali Radix. Medicines (Basel). 2018; 5(2). PMC: 6023478. DOI: 10.3390/medicines5020046. View

Dong P, Li H, Yu X, Li Q, Liu J, Liu C . Effect and mechanism of "Danggui-kushen" herb pair on ischemic heart disease. Biomed Pharmacother. 2021; 145:112450. DOI: 10.1016/j.biopha.2021.112450. View

Ren-an Q, Juan L, Chuyuan L, Wenjuan F, Chunyan H, Xuemei Y . Study of the protective mechanisms of Compound Danshen Tablet (Fufang Danshen Pian) against myocardial ischemia/reperfusion injury via the Akt-eNOS signaling pathway in rats. J Ethnopharmacol. 2014; 156:190-8. DOI: 10.1016/j.jep.2014.08.023. View

Yang X, He T, Han S, Zhang X, Sun Y, Xing Y . The Role of Traditional Chinese Medicine in the Regulation of Oxidative Stress in Treating Coronary Heart Disease. Oxid Med Cell Longev. 2019; 2019:3231424. PMC: 6409025. DOI: 10.1155/2019/3231424. View

Xue X, Deng Y, Wang J, Zhou M, Liao L, Wang C . Hydroxysafflor yellow A, a natural compound from Carthamus tinctorius L with good effect of alleviating atherosclerosis. Phytomedicine. 2021; 91:153694. DOI: 10.1016/j.phymed.2021.153694. View

Du C, Yang R, Song S, Wang Y, Kang J, Zhang R . Magnesium Lithospermate B Protects Cardiomyocytes from Ischemic Injury Via Inhibition of TAB1-p38 Apoptosis Signaling. Front Pharmacol. 2011; 1:111. PMC: 3095368. DOI: 10.3389/fphar.2010.00111. View

Zhang C, Zheng Y, Chen T, Wang S, Xu M . The utility of traditional Chinese medicine (Shenmai) in the cardiac rehabilitation after coronary artery bypass grafting: A single-center randomized clinical trial. Complement Ther Med. 2019; 47:102203. DOI: 10.1016/j.ctim.2019.102203. View

Gao S, Li L, Li L, Ni J, Guo R, Mao J . Effects of the combination of tanshinone IIA and puerarin on cardiac function and inflammatory response in myocardial ischemia mice. J Mol Cell Cardiol. 2019; 137:59-70. DOI: 10.1016/j.yjmcc.2019.09.012. View

Wang Z, Chen R, Li J, Chen J, Li W, Niu X . Puerarin protects against myocardial ischemia/reperfusion injury by inhibiting inflammation and the NLRP3 inflammasome: The role of the SIRT1/NF-κB pathway. Int Immunopharmacol. 2020; 89(Pt B):107086. DOI: 10.1016/j.intimp.2020.107086. View

10.

Chen Z, Quan L, Zhou H, Zhao Y, Chen P, Hu L . Screening of active fractions from Curcuma Longa Radix isolated by HPLC and GC-MS for promotion of blood circulation and relief of pain. J Ethnopharmacol. 2018; 234:68-75. DOI: 10.1016/j.jep.2018.09.035. View

11.

Chua Y, Ang X, Zhong X, Khoo K . Interaction between warfarin and Chinese herbal medicines. Singapore Med J. 2015; 56(1):11-8. PMC: 4325561. DOI: 10.11622/smedj.2015004. View

12.

Chen R, Jinn T, Chen Y, Chung T, Yang W, Tzen J . Active ingredients in Chinese medicines promoting blood circulation as Na+/K+ -ATPase inhibitors. Acta Pharmacol Sin. 2011; 32(2):141-51. PMC: 4009935. DOI: 10.1038/aps.2010.197. View

13.

Zhou Y, Li M, Song J, Shi Y, Qin X, Gao Z . The cardioprotective effects of the new crystal form of puerarin in isoproterenol-induced myocardial ischemia rats based on metabolomics. Sci Rep. 2020; 10(1):17787. PMC: 7575583. DOI: 10.1038/s41598-020-74246-y. View

14.

Feng H, Wang Z, Wang C, Zhu X, Liu Z, Liu H . Effect of Furostanol Saponins from Allium Macrostemon Bunge Bulbs on Platelet Aggregation Rate and PI3K/Akt Pathway in the Rat Model of Coronary Heart Disease. Evid Based Complement Alternat Med. 2019; 2019:9107847. PMC: 6612384. DOI: 10.1155/2019/9107847. View

15.

Huang Y, Jiang W, Xiao Y, Wang Y . Multiobjective optimization on antiplatelet effects of three components combination by quantitative composition-activity relationship modeling and weighted-sum method. Chem Biol Drug Des. 2014; 84(5):513-21. DOI: 10.1111/cbdd.12338. View

16.

Li J, Liang Q, Sun G . Interaction between Traditional Chinese Medicine and Anticoagulant/Antiplatelet Drugs. Curr Drug Metab. 2019; 20(9):701-713. DOI: 10.2174/1389200220666190827160212. View

17.

Ma Y, Li H, Yue Z, Guo J, Xu S, Xu J . Cryptotanshinone attenuates cardiac fibrosis via downregulation of COX-2, NOX-2, and NOX-4. J Cardiovasc Pharmacol. 2014; 64(1):28-37. DOI: 10.1097/FJC.0000000000000086. View

18.

Wang L, Ma R, Liu C, Liu H, Zhu R, Guo S . Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases. Curr Pharm Des. 2016; 23(7):1077-1097. PMC: 5421141. DOI: 10.2174/1381612822666161010105242. View

19.

Zhou Y, Zhang H, Peng C . Puerarin: a review of pharmacological effects. Phytother Res. 2013; 28(7):961-75. DOI: 10.1002/ptr.5083. View

20.

Shang Q, Xu H, Huang L . Tanshinone IIA: A Promising Natural Cardioprotective Agent. Evid Based Complement Alternat Med. 2012; 2012:716459. PMC: 3292221. DOI: 10.1155/2012/716459. View